Prognostic Value of Ki-67/MIB-1 Expression in Meningioma Patients: A Meta-Analysis.
Ki-67/MIB-1 is the most widely used immumohistochemical marker to measure cell proliferation in recent years, and its high expression is significantly related to high malignancy and short survival cycle. This meta-analysis was conducted to confirm the prognostic value of Ki-67/MIB-1 in meningioma patients. A comprehensive search was carried out of mainstream electronic databases including Pubmed, EMBASE, Google Scholar, Web of Science, and Cochrane Library, and finally 10 studies containing 1,414 meningioma patients were included in the meta-analysis. The combined hazard ratio (HR) and its 95% confident intervals (CIs) were used to evaluate the association between Ki-67/MIB-1 expression and survival. High expression of Ki-67/MIB-1 was found to be significantly associated with low RFS (HR 3.31, 95% CI 1.62-6.78, P = 0.001, random effect) and PFS(HR 3.14, 95% CI 1.64-6.00, P = 0.001, fixed effect). Subgroup analysis was conducted to explore the potential heterogeneity. Results of the meta-analysis indicated that high expression of Ki-67/MIB-1 may serve as a useful biomarker for poor prognosis in meningioma patients.